Meet the management of Neovacs, a biotechnology company specializing in the research and development of therapeutic vaccines for the treatment of autoimmune diseases. The results of its Phase IIB clinical study in the treatment of lupus will be announced by the end of June 2018. What to expect?
Wednesday, May 16, 2018
NORMANDY HOTEL, 7 rue de l’Echelle, 75001 Paris
6:45 p.m. OPENING
7 p.m. NEOVACS CONFERENCE
Miguel SIELER, General Manager
Thérèse CROUGHS, MD, Medical Director
Baptiste POURTOUT, Administrative and Financial Director
-Fashion mode of technology
-What to expect from the results of the Phase IIb clinical study in lupus?
8.30 p.m. Cocktail, discussions with management and networking
